List view / Grid view
18 July 2016 | By Victoria White, Digital Content Producer
At an estimated $4billion a year, the reference product, Humira, is among the European Union's largest single drug expenditures...
With Remsima being on the market for a year, European Pharmaceutical Review caught up with Celltrion Healthcare to find out more about biosimilars...
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
24 May 2016 | By Victoria White, Digital Content Producer
Vedolizumab is the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active UC...
24 May 2016 | By Victoria White, Digital Content Producer
Prof. Dr. Axel Dignass said the data show that Adacolumn provided clinical benefit in steroid-dependent patients with UC with previous failure to biologics...
6 April 2016 | By Victoria White, Digital Content Producer
With this approval, Celltrion's Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US...
21 March 2016 | By Victoria White
GO-COLITIS evaluated the efficacy of Simponi (golimumab) in inducing and maintaining clinical response in patients with moderate to severe ulcerative colitis...
6 January 2016 | By Victoria White
Newly presented data from the largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab...
28 October 2015 | By Victoria White
New clinical data indicate no differences in efficacy, adverse events and immunogenicity when patients with inflammatory bowel disease are switched to biosimilar infliximab Remsima from originator infliximab...
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
